Research
Hormonal
ATF3 plays a dual role in prostate cancer, acting as a tumor suppressor by inhibiting androgen signaling and AKT, but also as an oncogene by promoting cell proliferation and metastasis via SUMOylation.
ATF3's role in prostate cancer is complex. It can suppress tumors by blocking androgen signals but can also promote cancer if modified by SUMOylation. This complexity makes it a challenging but potentially valuable target for therapy.
ModerateQualifiesMEDIUM confidence
These findings indicate that ATF3 plays dual roles as both an oncogene and tumor suppressor gene in prostate cancer regulation.
Why this rating
Based on cell line and mouse model studies; no human clinical outcomes reported.
Source
Master Regulator Activating Transcription Factor 3 (ATF3) in Metabolic Homeostasis and Cancer
Hui‐Chen Ku et al. · Frontiers in Endocrinology · 2020
DOI 10.3389/fendo.2020.00556
narrative_reviewCited 349×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- ATF3 acts as a master regulator of metabolic homeostasis and oncogenesis, functioning as a context-dependent hub that can either suppress or promote disease states depending on tissue type and cellular stress.Moderate
- ATF3 induction by synthetic agents like ST32da promotes adipocyte browning and inhibits lipogenesis, potentially offering a mechanism to combat obesity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →